Additions to the Board of Directors, Trial Updates, New Contracts, and Management Changes - Research Report on Charles River Laboratories, Synageva, ICU Medical, ICON, and Hanger

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories International, Inc. (NYSE: CRL), Synageva BioPharma Corporation (NASDAQ: GEVA), ICU Medical, Inc. (NASDAQ: ICUI), ICON plc (NASDAQ: ICLR), and Hanger, Inc. (NYSE: HGR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Charles River Laboratories International, Inc. Research Report

On December 3, 2013, Charles River Laboratories International, Inc. (Charles River Laboratories) announced the appointment of Craig B. Thompson, M.D., President and CEO of Memorial Sloan-Kettering Cancer Center, to the Company's Board of Directors. Charles River Laboratories informed that Thompson's extensive experience with both global pharmaceutical companies and leading academic institutions in the fields of cancer biology and immunology will provide the Company with a unique combination of expertise. The Company's Board of Directors also announced that it has established a new Science and Technology Committee, with Thompson as the Chairman. The Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a37e_CRL

--

Synageva BioPharma Corporation Research Report

On December 2, 2013, Synageva BioPharma Corporation announced that it has met the enrollment target of 50 patients in ARISE, a global Phase 3 trial with sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL deficiency). The Company reported that it expects to exceed the planned number of 50 patients to accommodate individuals still in the screening process. The final patient is expected to be randomized by the end of 2013. Synageva further expects to report top-line results from the ARISE trial during H2 2014. The Full Research Report on Synageva BioPharma Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8624_GEVA

--

ICU Medical, Inc. Research Report

On December 2, 2013, ICU Medical, Inc. (ICU Medical) announced that it has been awarded a six-year group purchasing contract from Premier Inc. (Premier) for the Diana hazardous drug compounding system, the world's first user-controlled, automated sterile compounding system for the accurate, safe, and efficient preparation of hazardous drugs. ICU Medical informed that the contract takes effect in 2014 and also marks the first time the Diana system has been on contract with a group purchasing organization. The Company has announced a new version of the Diana system, incorporating a barcode scanning system, which will be debuted at the American Society of Hospital Pharmacists (ASHP) midyear clinical meeting to be held on December 8 to December 12, 2013, in Orlando, Florida. "Premier has long recognized the importance of enabling hazardous drug safe handling processes for its members, and the addition of the Diana system to Premier contract is another example of putting safety first," said Richard Costello, Senior Vice President of Sales at ICU Medical. "With the Diana system, Premier member facilities now have access to the latest technology for the safe, sterile preparation of hazardous drugs." The Full Research Report on ICU Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/be3b_ICUI

--

ICON plc Research Report

On November 27, 2013, ICON plc (ICON) announced the appointment of Manuel Ploch to the position of General Manager, Japan. Under the position, Ploch leads all of the Company's operations in the region, including offices in Tokyo and Osaka. Prior to joining ICON, he was an independent consultant to various US, European, and Asian pharmaceutical and biotech companies entering the Japanese market. The Full Research Report on ICON plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fbb0_ICLR

--

Hanger, Inc. Research Report

On November 21, 2013, Hanger, Inc. (Hanger) announced the election of Christopher B. Begley, retired Executive Chairman of the Board of Directors and former CEO of Hospira, as a director to Hanger's Board of Directors with immediate effect. "As former CEO of a global hospital products company with over 40 years' experience, Chris brings a deep understanding of the healthcare industry and proven expertise in operations and strategic growth," said Vinit Asar, President and CEO of Hanger. "We are confident Chris will provide additional leadership and expert healthcare acumen to our Board as we continue Hanger's commitment to empowering human potential." The Full Research Report on Hanger, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0e96_HGR

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner